ClinicalTrials.gg
Active, not recruitingNCT06907875FSHDUpdated Aug 19, 2026

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

A Phase 1/2 interventional study of EPI-321 in Facioscapulohumeral Muscular Dystrophy, sponsored by Epicrispr Biotechnologies, Inc.. Active, not recruiting at 7 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Epicrispr Biotechnologies, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.

Planned enrollment
18th of 21
12 · median 51
Started
2025
with 4 others
Phase 1/2
8 of 32
none open now
Primary completion
2027-07
later than 2 of 12 live
Registered
28th of 32
by date
Lead sponsor
1 of 32
Epicrispr Biotechnologies, Inc.

Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 2 of the 12 other live ones, and was the 28th registered.

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Open to participants now

8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are:

How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working?

Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321.

Read the detailed description

EPI-321 is an investigational drug product comprising a recombinant adeno-associated viral vector, serotype rh74 (AAVrh74), for the delivery of genetic material encoding an epigenetic editor designed to address the root case of FSHD. AAVrh74 has been shown to transduce human skeletal muscle efficiently in the clinical experience. EPI-321's transgene product, a non-cutting, nuclease-dead mini, clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein (dCasONYX) with fuse epigenetic modulators, is designed to selectively bind the D4Z4 repeat region via the accompanying guide RNA, methylate CpG groups within the region near the DUX4 gene on chromosome 4q35, and thus repress the expression of toxic DUX4 protein, ameliorating the downstream pathology that drives FSHD. As it is under a muscle-specific promoter, the dCasONYX-fused protein is expected to be preferentially and actively expressed in muscle tissue following a single intravenous (IV) dose.

EPI-321-02 clinical trial is an open label dose ascending study of EPI-321 for safety and tolerability to determine the best dose for a future trial of drug activity. Two dose levels will be evaluated. In addition, this study will collect secondary outcome data on muscle function, imaging characteristics, and other markers of disease activity at the baseline and throughout the study to assess their utility as measures of drug activity in a future clinical trial.

03

Conditions studied

  • Facioscapulohumeral Muscular Dystrophy

Keywords

  • Facioscapulohumeral Muscular Dystrophy
  • EPI-321
  • Muscular Dystrophy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide
  • Male or female 18 to 75 years of age
  • Clinical diagnosis of FSHD with genetic Type 1
  • FSHD Ricci clinical severity score 2 to 4 (on 5-point scale)
  • Has adequate liver function
  • Has adequate kidney function

Exclusion criteria

Exclusion Criteria:

  • Has an anti-AAVrh74 total binding antibody titer > 1:400
  • Requires a walker or wheelchair for ambulation
  • Pregnant and/or breastfeeding at baseline or is planning to become pregnant during the first 12 months following EPI-321 administration
  • Has FSHD Type 2
  • Has a concurrent or past medical conditions could jeopardize the safety of the participant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    EPI-321 Cohort 1 Single IV Dose

    Single IV infusion of a target dose of 2x10\^13 vg/kg

    Biological: EPI-321

  • Experimental
    EPI-321 Cohort 2 Single IV Dose

    Single IV infusion of a target dose of 4x10\^13 vg/kg

    Biological: EPI-321

Interventions

  • BiologicalEPI-321

    EPI-321 IV Infusion

06

What researchers measure

Primary outcomes

  1. Frequency of AEs and EPI-321 Related Adverse Reactions and Serious Adverse Reactions

    All AEs, regardless of assessed relatedness to EPI-321, will be collected from the time of informed consent signature until the end of study participation. The Investigator is responsible for assessing the severity of an AE according to the NCI-CTCAE version 5.0.

    Time frame: Baseline to up to 5 years.

Secondary outcomes

  1. Vector Copy Number

    Change in vector copy number (as measured by vg/dg) within skeletal muscle biopsies.

    Time frame: Baseline, 3 and 12 months

  2. EPI-321 Cargo Transcriptional Activity

    Change in EPI-321 cargo transcriptional activity within skeletal muscle biopsies.

    Time frame: Baseline, 3 and 12 months

  3. DUX4 Expression

    Change in the expression of DUX4 and downstream markers (DUX4 Composite Score) within skeletal muscle biopsies.

    Time frame: Baseline, 3 and 12 months

  4. Methylation Status

    Change from baseline in the methylation status of the 4q35 D4Z4 region within skeletal muscle biopsies at 3 and 12 months.

    Time frame: Baseline, 3 and 12 months

07

Study locations

7 sites
  • David Geffen School of Medicine at University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Rare Disease Research
    Atlanta, Georgia 303329, United States
  • Kennedy Krieger Institute, Center for Genetic Muscle Disorders
    Baltimore, Maryland 21205, United States
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01605, United States
  • Utah Program for Inherited Neuromuscular Disorders - University of Utah
    Salt Lake City, Utah 84112, United States
  • Royal Alfred Hospital
    Sydney, New South Wales 2050, Australia
  • Pacific Clinical Research Network
    Auckland, New Zealand 0622, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 2, 2025
StartActual
May 8, 2025
Primary completionEst.
Jul 7, 2027
CompletionEst.
Apr 30, 2032
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06907875
Lead sponsor
Epicrispr Biotechnologies, Inc.
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
May 8, 2025
Primary completion
Jul 7, 2027 (estimated)
Completion
Apr 30, 2032 (estimated)
Last update
Aug 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion